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Abstract
Background: Klotho, is a transmembrane protein, performs as a circulating hormone and upstream modulator of
the insulin-like growth factor-1 receptor (IGF-1R), fibroblast growth factor (FGF), and Wnt signaling pathways. These
pathways are involved in the development and progression of B cell lymphoma. We aimed to explore the
expression pattern and functional mechanism of Klotho in diffuse large B cell lymphoma (DLBCL).
Methods: Immunohistochemistry (IHC) and western blotting were performed to detect the expression level of
Klotho in DLBCL patients and cell lines. Tumor suppressive effect of Klotho was determined by both in vitro and
in vivo studies. Signaling pathway activity was assessed by western blotting.
Results: Remarkable lower expression levels of Klotho were observed in DLBCL patients and cell lines. Enforced
expression of Klotho could significantly induce cell apoptosis and inhibit tumor growth in DLBCL. Upregulation
of Klotho resulted in declined activation of IGF-1R signaling, accompanied with decreased phosphorylation of
its downstream targets, including AKT and ERK1/2. Moreover, xenograft model treated with either Klotho
overexpression vector or recombinant human Klotho administration presented restrained tumor growth and
lower Ki67 staining.
Conclusions: Our findings establish that Klotho performs as a tumor suppressor and modulator of IGF-1R signaling
in DLBCL. Targeting Klotho may provide novel strategies for future therapeutic intervention.
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Background
Diffuse large B cell lymphoma (DLBCL) is the most
common form of non-Hodgkin lymphoma (NHL),
accounts for nearly 40% of all newly diagnosed cases
[1]. This disease presents as an aggressive process
and exhibits high heterogeneity in gene expression
and clinical outcomes [2, 3]. Although majority of
DLBCL patients could be cured by anthracycline-
based chemotherapies combined with rituximab, one
third of them presented refractory or relapsed process
[4, 5]. Therefore, more effective treatment strategies
based on novel therapeutic targets and molecular
oncogenic pathways are still needed.
Klotho is an anti-aging gene originally identified in
1997 [6]. Kuro-o et al. [6, 7] found that Klotho-deficient
mice developed multiple premature aging syndromes,
whereas overexpression of Klotho extended the lifespan
of mice. The Klotho gene is located in chromosome
13q12 in human with the size of 50 kb [6]. It encodes a
single-pass transmembrane protein, which consists of an
extracellular domain, a single transmembrane domain,
and an intracellular domain. The intracellular domain is
very short and has no clear functions. Membrane Klotho
functions as an obligate co-receptor of fibroblast growth
factor 23 (FGF23) to regulate phosphate homeostasis [8].
The extracellular domain (secreted Klotho) could be
released into the serum and functions as a circulating
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hormone to regulate the activity of oxidative stress, mul-
tiple growth factor receptors, and ion channels [9, 10].
The tumor suppressive activity of Klotho was first
identified in breast cancer in 2008 [11]. Recent investiga-
tions have implicated that Klotho is extensively down-
regulated in several solid tumors, including cervical
cancer, pancreatic cancer, melanoma, and several digest-
ive neoplasm [12]. In these malignancies, Klotho was
elucidated to be a modulator of several signaling path-
ways, including the FGF signaling, insulin-like growth
factor-1 receptor (IGF-1R), and Wnt pathways, which
are also involved in the pathogenesis of hematological
malignancies [10, 13–15]. However, the role of Klotho in
hematological malignancies has not been reported.
A large number of aberrant receptor tyrosine kinases
(RTKs) have been found in hematological malignancies
[16, 17], but they are still indefinite in DLBCL. IGF-1R is
a RTK primarily activated by its cognate ligands, IGF-1,
and IGF-2. It plays a crucial role in the establishment
and progression of tumors by regulating proliferation,
self-renewal, apoptosis, and drug resistance of cancer
cells [18–20]. Activation of IGF-1R following IGF-1
treatment results in phosphorylation of downstream sig-
naling cascades, including PI3K/AKT and MAPK/ERK
[19]. Blockade of PI3K/AKT signaling could restrain cell
survival and function of lymphocytes [21, 22]. Activation
of MAPK/ERK signaling promotes cell proliferation and
metastasis of cancer cells [23]. Strategies to block
IGF-1R pathway in solid malignancies are being tested
in clinical trials [24], whereas the function of IGF-1R
signaling in DLBCL has been less studied [25].
In this present study, we aimed to assess the expres-
sion level and functional mechanism of Klotho in
DLBCL. We identified reduced expression of Klotho in
DLBCL for the first time. Noted inhibition of cell growth
and induction of apoptosis were observed in DLBCL
with Klotho overexpression. Tumor growth was re-
strained by administration of Klotho protein in xenograft
model of DLBCL. Our findings demonstrated that Klotho
was a tumor suppressor and modulator of IGF-1R signal-
ing in DLBCL, indicating that targeting Klotho may
provide novel therapeutic strategy in DLBCL.
Methods
Patients
This study was approved by the Medical Ethical Com-
mittee of Shandong Provincial Hospital affiliated to
Shandong University. The paraffin-embedded archived
samples from 50 newly diagnosed DLBCL patients and
20 reactive hyperplasia patients were collected. Samples
of patients with reactive hyperplasia were referred as
control. Histological diagnoses were established accord-
ing to the WHO classification [26]. Peripheral blood
mononuclear cells (PBMCs) from the whole blood of
healthy donors were isolated using Ficoll-Hypaque dens-
ity gradient centrifugation (TBD science, Tianjin, China).
Normal peripheral blood CD19+ B cells were purified
from freshly isolated PBMCs using CD19+ magnetic
microbeads kit (Miltenyi Biotec, Bergisch Gladbach,
Germany). Cells were incubated with beads for 15 min
at 4 °C while rotating. Purified CD19+ B cells were
selected according to the manufacturer’s protocols. The
purity of isolated populations was assessed by FACS
analysis, and cells with >90% purity were collected. All
samples were obtained with informed consent in accord-
ance with the Declaration of Helsinki.
Cell lines and reagents
Human DLBCL cell lines LY1 and LY8 were cultured in
Iscove modified Dulbecco medium with 10% heat-
inactivated fetal bovine serum. The medium contains 1%
penicillin/streptomycin mixture and 2 mmol/l glutam-
ine. CD19+ B cells and PBMCs obtained from three
healthy donors were used as controls (N1, N2, and N3
cells). Recombinant human Klotho (rhKL) and recom-
binant human IGF-1 were obtained from PeproTech
(Rocky Hill, NJ, USA), and adriamycin (ADR) was
bought from Actavis (S.p.A, Italy).
Cell transfection
Lentivirus vectors either encoding Klotho or an empty
lentiviral vector were from Genechem (Shanghai, China).
Lentivirus transfection was carried out according to
the manufacturers’ instruction. Infection efficiencies
were assessed by green fluorescent protein (GFP)
through flow cytometry. The stably transfected cells
were selected 48 h later with 5 μg/ml puromycin
(Sigma-Aldrich, USA).
Quantitative real-time PCR
Total RNA was extracted using RNAiso Plus (TaKaRa,
Dalian, China). Reverse transcription reaction was con-
ducted with the reverse transcription reagents (TaKaRa,
Dalian, China). Amplification reactions were performed
with SyberGreen (TaKaRa, Dalian, China) in LightCycler
480II (Roche, Basel, Swizerland). Klotho-specific primers
were as follows: forward, 5′-AGCAATCTGGTCTGAAT
AACACTGG; reverse, 5′-CATGTTTCAGCGTGAAAG
TTCAAAG. Relative quantification was calculated using
the △△CT method.
Immunohistochemistry (IHC) and hematoxylin-eosin
staining
The 4-μm-thick formalin-fixed, paraffin-embedded tis-
sue sections were deparaffinized and hydrate. Antigen
retrieval was performed using 0.01 mol/l sodium citrate
buffer (pH 6.0) under high pressure followed by a 1-h
cool-down and rinses in phosphate buffer solution
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(PBS). Endogenous peroxidase was blocked with 3%
hydrogen peroxide in methanol for 15 min, followed by
incubation with normal serum to block non-specific
binding. The slides were then incubated overnight at 4 °
C with primary antibodies, anti-Klotho (1:150) or anti-
Ki67 (1:100). After washing, the tissue sections were
treated with the second antibody from SP reagent kit
(Zhongshan Goldenbridge, Beijing, China) for 30 min at
room temperature, followed by further treated with
strept avidin-horseradish peroxidase complex (SABC)
for 30 min at room temperature. After treated with
diaminobenzidine (DAB) Kit (ZhongshanGoldenbridge,
Beijing, China), the stained slides were counterstained
with hematoxylin and mounted. Negative control was
carried out with the primary antibody replaced by PBS.
IHC staining was scored by the proportion of positive
tumor cells. Five microscopic fields with the highest
immunoreactivity at ×400 magnification were evaluated
by two independent observers who were blinded to the
patients’ clinical data. Cases with at least 10% of tumor
cells with Klotho staining were considered as positive.
Fresh mice subcutaneous tumors were fixed in 4% para-
formaldehyde (PFA) and embedded with paraffin for
histological examinations. Sections with 4-μm thickness
were cut and stained with hematoxylin-eosin (H&E).
Western blotting
Cells were lysed in radio-immunoprecipitation assay
buffer (Shenergy Biocolor, Shanghai, China) together
with 1× phosphatase inhibitor cocktail (PhosSTOP;
Roche, Mannheim, Germany). The BCA assay (Shenergy
Biocolor, Shanghai, China) was performed to detect
protein concentration. Protein extracts (30 μg) were
then electrophoresed on SDS-polyacrylamide gels and
blotted from the gel onto polyvinylidene fluoride
membranes (Millipore, Billerica, MA, USA). Membranes
were incubated with the blocking solution (5% skim milk
in Tris-buffered saline containing 0.05% Tween-20) for
1 h at room temperature and then immunoblotted with
the indicated antibodies (1:1000 dilution) overnight at 4 °
C. After which, the membranes were washed with TBS-T
and then probed with the HRP-conjugated secondary anti-
bodies (Zhongshan Goldenbridge, Beijing, China) and the
electro-chemi-luminescence kit (Millipore, Billerica, MA,
USA). Chemiluminescent signals were detected using the
Amersham Imager 600 imaging system (General Electric,
USA). ImageJ software (ImageJ, NIH) was used to
quantify the protein bands normalized to control. Pri-
mary antibodies used were Klotho (Abcam, Cambridge,
MA, USA), phospho-IGF-1R (Tyr1135/1136), IGF-1R,
phospho-AKT(Ser473), total pan-AKT, Mcl-1, Caspase-3,
diphosphorylated and total ERK1/2 (Cell Signaling Tech-
nologies, Beverly, MA, USA), β-actin, and GAPDH
(Zhongshan Goldenbridge, Beijing, China). The experiments
were performed in triplicate with GAPDH or β-actin
(Zhongshan Goldenbridge, Beijing, China) as endogenous
control.
Cell proliferation assay
Cell proliferation was assessed by performing tripli-
cate assays with the Cell Counting Kit-8 (CCK-8)
assay (Enogene, Nanjing, China). DLBCL cells with
designed treatment were seeded in 96-well plates at a
density of 5000 cells/well for 48 or 24~96 h later.
Thereafter, the cells were incubated with 10 μl/well
CCK-8 for 4 h according to the manufacturer’s pro-
posal. Cell proliferation was detected by light absorp-
tion at 450 nm by Multiskan GO Microplate Reader
(Thermo Scientific, Rockford, IL, USA).
Flow cytometry analysis
Apoptosis of transfected DLBCL cells were detected by
Annexin V-PE/7-aminoactinomycin (7AAD) (BD Biosci-
ences, Bedford, MA, USA) assay according to the manu-
facturers’ instructions. DLBCL cells with designed
treatments were harvested and washed twice with ice-
cold PBS and incubated in 1× binding buffer (containing
5 μl Annexin V-PE and 5 μl 7AAD). After incubation in
the dark for 15 min, cells were subjected to the flow
cytometry. At least 10,000 events per sample were
acquired. Cells were discriminated into viable cells
(AnnexinV-PE−/7AAD−), dead cells (Annexin V-PE
−/7AAD+), apoptotic cells (Annexin V-PE+/7AAD−), and
necrotic cells (Annexin V-PE+/7AAD+). The rates of
apoptotic cells were acquired on a FACS-Navios Flow
Cytometer (Beckman Coulter, CA, USA). Data were
analyzed using FlowJo Version 7.6 software (Tree Star
Inc., OR, USA).
Elisa assay
Serum soluble Klotho levels were measured using the
Elisa kit (Immuno-Biological Laboratories, Gunma,
Japan), with a lower limit of assay of 6.15 pg/ml.
In vivo xenograft study
All animal experiments were performed in accordance
with the principles of the Institutional Animal Care.
Severe combined immunodeficiency (SCID) Beige female
mice of 5-week old were bought (Weitong Lihua Labora-
tory Animal Center, Beijing, China) and maintained in a
pathogen-free environment under controlled condition
of light and humidity. 1 × 107 LY1 cells (untransfected,
stably Klotho-overexpressing vector tranfected, or empty
control vector transfected, respectively), mixed with
100 μl Matrigel (BD Biosciences, Bedford, MA, USA),
were subcutaneously injected into the right inferior limb
of mice. Tumor size was measured by the digital caliper.
For the experiment with rhKL, SCID Beige mice were
Zhou et al. Journal of Hematology & Oncology  (2017) 10:37 Page 3 of 11
injected subcutaneously with 1 × 107 LY1 cells into the left
inferior limbs. Mice were treated with daily intraperitoneal
injections of rhKL (7.5 μg/kg) or PBS control (six mice
per group) for 2 weeks. The volume of tumor was esti-
mated using the equation V = (a × b2) × 0.5236, where a is
the largest dimension and b is the perpendicular diameter.
Statistical analysis
All statistical analyses were performed by using the statistic
software SPSS17.0 (SPSS Inc., Chicago, IL, USA) for
Windows. In vitro experimental results were presented as
mean ± SD of data obtained from three separate experi-
ments. Overall survival time was measured from the date of
diagnosis to the date of death or the last follow-up. Kaplan-
Meier analysis was performed to estimate the survival func-
tions. A log-rank test was used to assess survival differences.
Chi-square test was used to analyze the clinical characte-
ristics of patients. One-way analysis of variance (ANOVA)
or t tests were used to assess the differences between
groups. p < 0.05 was considered to be statistically significant.
Results
Klotho was downregulated in DLBCL and related to
tumor progression
Compared with reactive hyperplasia, expression level of
Klotho was significantly lower in DLBCL tissues (Fig. 1a).
Klotho positive rate was 14% (7 of 50) in DLBCL
whereas 80% (16 of 20) in reactive hyperplasia. To evalu-
ate the clinical significance of Klotho in DLBCL, clinical
and pathological characteristics of DLBCL patients were
analyzed. The expression level of Klotho was associated
with the Ann Arbor stage of DLBCL patients. Patients
with stage III or IV presented markedly lower Klotho
level than those with stage I or II (p = 0.002, Table 1). In
addition, Kaplan-Meier survival analysis were performed
based on the expression levels of Klotho (n = 50). The
median survival of patients in Klotho-positive group was
48.46 months, significantly longer than those in Klotho-
negative group (29.27 months, p = 0.045, Fig. 1b). We
next confirmed the expression of Klotho in DLBCL cell
lines. Klotho mRNA expression was detected in DLBCL
cell lines and normal CD19+ B cells. Significantly
decreased levels of Klotho mRNA expression were
observed in DLBCL cell lines (LY1 0.024 ± 0.037, LY8
0.002 ± 0001, Fig. 1c). Reduced expression levels of
Klotho protein were also noted in DLBCL cell lines
compared to human PBMCs (Fig. 1d).
Klotho inhibited growth of DLBCL
To further establish the biological function of Klotho,
human DLBCL cells were stably transfected with either
negative control lentivirus vectors (LV-Con) or Klotho-
Fig. 1 Klotho was downregulated in DLBCL and related to tumor progression. a Compared with reactive hyperplasia, expression level of Klotho
was significantly decreased in DLBCL tissues. Original magnification, ×100 (upper panel) and ×400 (lower panel). b Patients with Klotho negative
expression showed shorter survival than those with Klotho positive expression. c As detected by real-time quantitative PCR, lower levels
of Klotho mRNA expression were observed in DLBCL cell lines (LY1, LY8) than in CD19+ B cells (N1, N2, N3) (mean ± SD, n = 3, *p < 0.05).
d Protein expression levels of Klotho were detected in DLBCL cells and normal PBMCs. The ratios of relative protein expression level of
targets are indicated below the western blot
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overexpression lentivirus vectors (LV-KL). The upregula-
tion of Klotho levels were confirmed by quantitative
PCR and western blot (Fig. 2a, b). Cell proliferation rates
were evaluated by CCK-8 assay. Significant reduction of
cell proliferation was observed in LY1 and LY8 cells
transfected with LV-KL, compared with those trans-
fected with empty vector (Fig. 2c). Furthermore, we
investigated the anti-tumor effect of Klotho on DLBCL
xenografts in vivo. LY1 cells, stably expressing Klotho, or
the vector control cells were injected subcutaneously
into SCID Beige mice, respectively. Consistent with the
in vitro results, mice treated with Klotho overexpression
cells revealed remarkable reduction in tumor volume
compared to that transfected with empty vector (Fig. 2d).
Higher expression level of Klotho was identified in mice
treated with LV-KL-transfected LY1 cells (Fig. 2e). In
addition, we estimated the expression level of prolifera-
tive marker Ki67 [27, 28] in xenograft mice by IHC.
Lower level of Ki67 positive rate were observed in
LV-KL group (Fig. 2e).
Klotho promoted apoptosis of DLBCL cells
To investigate whether Klotho could promote the
apoptosis of DLBCL cells, Annexin-V-based apoptotic
assays were performed. Flow cytometry analysis indi-
cated that Klotho overexpression resulted in enforced
apoptosis rates in both LY1 (6.56 ± 0.71% in LV-Con vs.
16.41 ± 2.16% in LV-KL group, p = 0.002) and LY8 cells
(7.23 ± 0.65% in LV-Con vs. 16.03 ± 1.85% in LV-KL
group, p = 0.001, Fig. 3a, b). In addition, western blot
analysis confirmed the pro-apoptotic effects of Klotho.
Dramatically reduction of anti-apoptotic protein Mcl-1
and increased cleaved forms of Caspase-3 were observed
in DLBCL cell lines (Fig. 3c). Altogether, these results
indicate that upregulation of Klotho could promote the
apoptosis of DLBCL cells.
Klotho modulated the activation of IGF-1R signaling in
DLBCL
Having shown that Klotho could impair cell proliferation
and induce apoptosis in DLBCL, we next investigated
the molecular mechanisms responsible for the function
of Klotho. The IGF-1R pathway plays a vital role in the
development of hematological malignancies [14, 25, 29].
CCK-8 assay was conducted to assess the effect of
Klotho on IGF-1-induced cell proliferation. DLBCL cells
transfected with either LV-KL or LV-Con were treated
with IGF-1 or vehicle control in 0.5% FBS culture
medium for 24–96 h. In the groups untreated with
IGF-1, LV-KL transfection resulted in declined pro-
liferation of LY1 and LY8 cells compared to empty-
vector group. In the IGF-1-treated groups, we observed
that cell proliferation was less restored by IGF-1 in cells
transfected with LV-KL compared to that transfected
with LV-Con. Following addition of IGF-1, cell pro-
liferation of LV-Con-treated cells increased by up to
60%, whereas the only up to 40% enhancement of
cell proliferation was found in LV-KL transfected
cells (Fig. 4a).
As the IGF-1R signaling could be activated by IGF-1,
we explored the optimal activation dose and time of
IGF-1 in DLBCL cell lines. LY1 cells were transfected
with either LV-KL or LV-Con, serum starved for
48 h and treated with IGF-1 for the indicated times
and doses. Western blot was carried out to evaluate
the phosphorylation level of the IGF-1R. As shown
in Fig. 4b, the maximum activation occurred at
IGF-1 concentration of 50 ng/ml and at the time of
30 min after treatment. Then, we studied the ability
of Klotho to modulate activation of IGF-1R signaling
in DLBCL cells. Cells transfected with either LV-KL
or LV-Con were serum starved for 48 h, treated with
IGF-1 (50 ng/ml for 30 min) or vehicle control. Fol-
lowing treatment, cells were harvested and immuno-
blotting was conducted. Decreased phosphorylation
Table 1 Correlation between Klotho expression and clinical
characteristics of DLBCL patients
Characteristics No. of patients Klotho expression p value
Positive (%) Negative
Age (years)
<60 27 4(14.8%) 23 0.857
≥60 23 3(13.0%) 20
Gender
Male 26 2(7.7%) 24 0.181
Female 24 5(20.8%) 19
Ann Arbor stage
I or II 12 5(41.7%) 7 0.002
III or IV 38 2(5.3%) 36
B symptoms
Present 14 2(14.3%) 12 0.971
Absent 36 5(13.9%) 31
Subtype
GCB 15 2(13.3%) 13 0.929
Non-GCB 35 5(14.3%) 30
Serum LDH
Normal 35 5(14.3%) 30 0.929
Elevated 15 2(13.3%) 13
Extranodal involvement
Absent 28 4(14.3%) 18 0.45
Present 22 3(13.7%) 25
IPI score
0–2 35 6(17.1%) 29 0.328
3–5 15 1(6.7%) 14
LDH lactate dehydrogenase, IPI international prognostic index
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level of IGF-1R and its downstream targets, includ-
ing AKT and ERK1/2, were observed in cells tra-
nsfected with LV-KL (Fig. 4c). Furthermore, we
evaluated the modulation of Klotho on IGF-1R sig-
naling in DLBCL xenograft model. Enhanced expres-
sion of Klotho in LV-KL-treated mice was confirmed
by immunoblotting (Fig. 5d). Decreased phosphoryl-
ation of IGF1-R as well as its downstream targets
were observed in mice treated with LV-KL compared
to the control group (Fig. 4d). These results demon-
strated that Klotho may act as a modulator of IGF-1R
signaling contributed to the tumorigenesis of DLBCL
(Fig. 4e).
rhKL acted as an active form both in vitro and in vivo
We further investigated the activity of secreted Klotho
protein on DLBCL. To explore the effect of secreted
Klotho on proliferation of DLBCL cells, LY1 and LY8
cells were seeded and treated with rhKL. The rhKL
was found to be active and reduced the proliferative
ability of DLBCL cells by 30~40% at the concentra-
tion of 2 μg/ml (Fig. 5a, b). ADR is one of the most
commonly used drugs in the chemotherapeutic strat-
egy of DLBCL. We detected the function of Klotho
on cell responses to ADR. LY1 and LY8 cells were
treated for 48 h with rhKL, ADR, or their com-
bination, and cell proliferation was then evaluated.
Fig. 2 Klotho suppressed DLBCL growth. a, b Relative expression levels of Klotho were confirmed by quantitative PCR (mean ± SD, n = 3, **p < 0.01)
and western blot in stably transfected LY1 and LY8 cells compared to empty vectors. The ratios of relative protein expression level of
targets are indicated below the bands. c DLBCL cells transfected with LV-KL presented significantly lower level of cell proliferation than
those transfected with empty vector (mean ± SD, n = 3, **p < 0.01). d SCID mice with Klotho overexpression revealed significantly lower
tumor volume than those with empty vector (n = 6 per group, **p < 0.01). e H&E staining and IHC staining of Ki67 and Klotho were
performed in mice tumors. Original magnification, ×400
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Combination of rhKL (2 μg/ml) increased the sensi-
tivity of DLBCL cells to ADR (Fig. 5a, b).
The in vivo activity of rhKL in DLBCL xenograft
model was also detected. LY1 cells were injected sub-
cutaneously into the SCID Beige mice to build a DLBCL
xenograft model. After 15 days, the mice were treated
with daily intraperitoneal injection of either rhKL
(7.5 μg/kg, n = 6) or a control vehicle (n = 6) for 2 weeks.
Significant decreased tumor volumes were observed in
the mice treated with rhKL compared with those treated
with vehicle control (Fig. 5c). Moreover, reductive
expression level of proliferative marker Ki67 was found
in rhKL-treated mice (Fig. 5d).
In addition, we employed ELISA assays to test the
soluble Klotho levels in the serum of 30 initially diag-
nosed DLBCL patients and 15 healthy volunteers. Lower
serum Klotho levels were noted in DLBCL patients
(628.54 ± 219.39 pg/ml) than the control subjects
(818.87 ± 241.51 pg/ml, p = 0.045, Fig. 5e).
Discussion
In this study, our observations identified for the first
time that Klotho, an anti-aging gene, as a potential
tumor suppressor in DLBCL tumorigenesis. Klotho was
downregulated in human DLBCL and inhibited the
growth of DLBCL both in vitro and in vivo. Upregula-
tion of Klotho resulted in declined activation of IGF-1R
signaling pathway in DLBCL.
We identified remarkable reduced expression of Klotho
in DLBCL tissues and cell lines, whereas higher expression
in reactive hyperplasia and CD19+ B cells from normal
donors. Decreased level of Klotho was associated with
advanced stage and more aggressive disease process in
DLBCL. Tumor suppressive activity of Klotho has been
reported in several human solid malignancies, but never
in hematological cancers [30–33]. Recent investigations
elucidated that epigenetic mechanisms, including pro-
moter methylation and histone deacetylation, contributed
to the reduced Klotho expression in human breast cancer,
cervical cancer, and hepatocellular carcinomas [34–36].
The similar mechanism may be involved in DLBCL. At
present, the diagnosis of DLBCL is mainly based on the
biopsy histopathology and IHC [37]. With the deepening
of additional studies, lower expression of Klotho may
serve as a potential marker for the pathological diagnosis
of DLBCL.
DLBCL is a high-grade heterogeneous disorder defined
by heterogeneity in clinical and biological characteristics
Fig. 3 Klotho promoted apoptosis of DLBCL. a, b Enforced expression of Klotho resulted in increased apoptosis rates in LY1 and LY8 cells
assessed by flow cytometric analysis with Annexin V-PE/7AAD staining (mean ± SD, n = 3, **p < 0.01). c Declined expression levels of Mcl-1 and
increased levels of activated Caspase-3 were observed in LV-KL-treated DLBCL cells. The ratios of relative protein expression level of targets are
indicated below the bands
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Fig. 4 (See legend on next page.)
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[1, 38, 39]. Personalized prognostic stratification and
targeted therapeutic strategies are urgently needed to
improve the outcomes of DLBCL patient [40]. Ki67 as a
proliferative marker performed as a poor prognostic
marker in DLBCL [27]. In this study, we discovered that
DLBCL xenograft mice with Klotho overexpression
exhibited significantly lower Ki67 staining positive rate
than that without Klotho upregulation.
As Klotho exists in both membrane-bound form and
secreted form, the secreted Klotho could be shed and
released into the circulation [7]. Recent investigation
elucidated the low serum level of Klotho in renal cell
(See figure on previous page.)
Fig. 4 Klotho modulated activation of IGF-1R pathway in DLBCL. a IGF-1-induced DLBCL cell (LY1 and LY8) proliferation is inhibited by Klotho
overexpression. LY1 and LY8 cells were transfected with LV-KL or LV-Con, starved for 48 h and treated by IGF-1 (50 ng/ml) and analyzed by CCK-8
assay (mean ± SD, n = 3, *p < 0.05, **p < 0.01). b LY1 with stable transfection of LV-KL or LV-Con were serum starved for 48 h and treated with
IGF-1 (50 ng/ml) for the indicated times or IGF-1 (30 min) for the indicated doses. After treatment, cells were harvested and analyzed by western
blot. c LY1 and LY8 cells transfected with LV-KL or LV-Con, serum starved for 48 h, and treated with IGF-1 (50 ng/ml, 30 min). Western blot was
conducted to assess the phosphorylated (p) and total (t) protein levels of IGF-1R, AKT, and ERK1/2. The ratios of relative protein expression level
of targets are indicated below the bands. d Decreased activation of IGF1-R signaling was observed in LV-KL-treated mice. The ratios of relative
protein expression level of targets are indicated below the bands. e Schematic description of Klotho mediated IGF1R signaling
Fig. 5 rhKL acted as an active form in vitro and vivo. a, b LY1 and LY8 cells were treated with rhKL, ADR, their combination, or a vehicle control.
CCK-8 assay was conducted after 48 h (mean ± SD, n = 3, *p < 0.05 for comparison between treated cells and control, **p < 0.05 between Klotho
and ADR combination versus ADR alone). c LY1 cells were injected subcutaneously into the left inferior legs of SCID Beige mice. The mice were
treated with daily intraperitoneal injections of rhKL (7.5 μg/kg) or vehicle control (PBS) for 2 weeks. Tumor volumes were measured every 2 days
(n = 6 per group, *p < 0.05). d H&E staining and IHC staining with Ki67 were performed. Original magnification, ×400. e Lower serum Klotho levels
were detected by Elisa in DLBCL patients than the control subjects
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carcinoma [41]. Low serum Klotho level was an inde-
pendent adverse prognostic factor for cancer-specific
and progression-free survival in RCC [41]. However,
the level of serum soluble Klotho was unchanged in
multiple myeloma [42]. Thus, the diagnostic role of
secreted Klotho in human cancer remains controver-
sial. In this study, we identified the decreased level of
serum Klotho in DLBCL patients. The correlation of
serum Klotho with disease diagnosis and progression
still needs further exploration. Larger number of the
included patients will better confirm the role of
serum Klotho in DLBCL.
Importantly, our study illuminated that Klotho effect-
ively inhibited the growth of DLBCL cells. Overexpres-
sion of Klotho significantly inhibited cell proliferation
and induced cell apoptosis in DLBCL. We also discov-
ered that efficacy of ADR could be enhanced by com-
bination with rhKL in DLBCL cells. This finding
suggested the potential of Klotho in therapeutic inter-
vention of DLBCL. Our in vivo investigations demon-
strated that upregulation of Klotho, either by LV-KL
transfection or rhKL administration, congruously led to
inhibitory effect in the tumor growth of xenograft
model of DLBCL. This will pave the way for rational
design of Klotho-based molecular products in DLBCL.
Nevertheless, pharmacokinetic investigations are still
required to explore the optimal dose and adverse reac-
tion of rhKL in the use of either single agent treatment
or drug combination.
Significantly, we also found that Klotho could inhibit
the activation of IGF-1R signaling in DLBCL. Induction
of IGF-1R signaling was involved in the pathogenesis of
hematological malignancies [13]. Recently, Stromberg
et al. reported the involvement of IGF-1R and the anti-
tumor effects of specific IGF-1R inhibitors in DLBCL
tumorigenesis [25]. Structure-function analysis of Klotho
indicated that Klotho could interact with the IGF-1R
[43]. Klotho-induced inhibition of IGF-1R signaling may
act as a novel mechanism involved in the development
of DLBCL. Apart from IGF-1R signaling, many other
pathways have been confirmed to be modulated by
Klotho in tumorigenesis. The most studied is the FGFR-
Klotho axis, and Klotho could act as cofactor of endo-
crine FGFs to bind and induce the activation of FGFRs
in breast, pancreatic, and prostate cancers [11, 30, 44].
Deregulation of Wnt signaling pathway plays a critical
role in the pathogenesis of cancers [45–47]. It was
proved that Klotho participated in tumorigenesis partly
through restraining the Wnt signaling pathway [48]. The
modulation of Klotho on these pathways in DLBCL is
poorly understood. In spite of the important discoveries
revealed by these studies, there are also limitations on
the detailed mechanisms and the cross-talks of them
involved in Klotho deregulation.
Conclusions
Taken together, our findings identified that Klotho
performs as tumor suppressor and modulator of IGF-1R
signaling in the DLBCL. Overexpression of Klotho may
be a predictive marker for favorable outcome in DLBCL.
Klotho reinforces the response of DLBCL cells to
chemotherapeutic drug. Being an endogenous circulating
hormone, the secreted Klotho could function as an
active form and inhibit the tumor growth effectively
both in vitro and in vivo. This study illuminates Klotho
as a potential target for future therapeutic strategies.
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